
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina's clinical consumables revenue demonstrated a mid-single-digit year-over-year increase, indicating ongoing demand and customer acquisition, particularly with the MiSeq i100 Plus appealing to new-to-sequencing customers. The company's strengthened funding outlook from China and the National Institutes of Health (NIH) further supports its positive trajectory in the market. Additionally, Illumina has raised its non-GAAP diluted earnings per share guidance to a range of $4.45 to $4.55, reflecting favorable adjustments and underlying business growth.
Bears say
Illumina's revenue outlook for 3Q25 indicates a projected constant currency decrease of 1.5-2.5% year-over-year, with reported revenue guidance suggesting a decline to between 1.06-1.07 billion. The company anticipates a significant drop in instruments revenue, specifically a decline of 4-6% year-over-year, contrasting with a modest growth in sequencing consumables of only 1-3% excluding China. Additionally, a significant reduction in NovaSeq X shipments compared to both the previous quarter and year-ago levels further underscores concerns regarding Illumina's sales performance and market demand.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares